Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05151484 · ClinicalTrials.gov registry record · Phase 4
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
A Phase 4 study of Age-Related Osteoporosis, sponsored by Madhumathi Rao.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05151484 is a Phase 4 study of Age-Related Osteoporosis that is actively recruiting participants, run by Madhumathi Rao. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05151484, a Phase 4 study of Age-Related Osteoporosis, is actively recruiting participants, sponsored by Madhumathi Rao.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Osteoporosis affects 24.5% of women over 65 and results in fracture-related hospital admissions exceeding those of heart attacks, strokes and breast cancer combined. Current treatment options do not account for differences between age-related and estrogen deficiency related osteoporosis, because of the need for bone biopsies for determination. This study will establish a paradigm-shifting individualized treatment protocol for age-related osteoporosis and a non-invasive method for its determination, thereby reducing the major health problems and enormous burden on society and the elderly related to this disease.
Conditions Studied
Interventions
- DRUG Teriparatide
- DRUG Alendronate
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05151484
The ClinicalTrials.gov registry entry for NCT05151484 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madhumathi Rao, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-Related Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Teriparatide is the first listed.
NCT05151484 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT05151484 about?
NCT05151484 is a clinical study titled "Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover". Osteoporosis affects 24.5% of women over 65 and results in fracture-related hospital admissions exceeding those of heart attacks, strokes and breast cancer combined. Current treatment options do not account for differences between age-related and estrogen deficiency related osteoporosis, because of ...
What is the current status of trial NCT05151484?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2022-03-21. Estimated completion is 2026-08-31.
What conditions does trial NCT05151484 study?
This clinical trial studies the following conditions: Age-Related Osteoporosis.
What interventions are being tested in trial NCT05151484?
The interventions under investigation include: Teriparatide (DRUG), Alendronate (DRUG).
Who is sponsoring clinical trial NCT05151484?
This trial is sponsored by Madhumathi Rao, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05151484 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-Related Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.